{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:22:21Z","timestamp":1793323341031,"version":"4.5.0"},"update-to":[{"DOI":"10.1002\/14651858.cd013424","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T00:00:00Z","timestamp":1625616000000}}],"reference-count":155,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd013424.pub2","type":"journal-article","created":{"date-parts":[[2021,7,7]],"date-time":"2021-07-07T12:07:57Z","timestamp":1625659677000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D"],"prefix":"10.1002","volume":"2021","author":[{"given":"Takashi","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Healthcare Epidemiology; Kyoto University Graduate School of Medicine\/School of Public Health; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasukazu","family":"Hijikata","sequence":"additional","affiliation":[{"name":"Department of Healthcare Epidemiology; Kyoto University Graduate School of Medicine\/School of Public Health; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiko","family":"Matsubara","sequence":"additional","affiliation":[{"name":"Department of Nephrology; Hiroshima University Hospital; Hiroshima Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Psychiatry; Soseikai General Hospital; Kyoto Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,7,7]]},"reference":[{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0001|cit1","first-page":"S377","article-title":"Bone mineral density and bone turnover marker changes with sequential abaloparatide\/alendronate: Results of ACTIVExtend [abstract no: MO0655]","volume":"32","author":"Bilezikian","year":"2017","journal-title":"Journal of Bone & Mineral Research"},{"issue":"12","key":"10.1002\/14651858.CD013424.pub2-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1080\/03007995.2019.1656955","article-title":"Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial","volume":"35","author":"Bilezikian","year":"2019","journal-title":"Current Medical Research & Opinion"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013424.pub2-BIB0003|cit3","first-page":"S264","article-title":"Abaloparatide-SC has minimal effects in subjects with mild or moderate renal impairment: Results from the ACTIVE trial [abstract no: SU0282]","volume":"31","author":"Bilezikian","year":"2016","journal-title":"Journal of Bone & Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/jbmr.2991","article-title":"Effects of abaloparatide-sc on fractures and bone mineral density in subgroups of postmenopausal women with osteoporosis and varying baseline risk factors","volume":"32","author":"Cosman","year":"2017","journal-title":"Journal of Bone & Mineral Research"},{"issue":"7","key":"10.1002\/14651858.CD013424.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.bone.2016.11.004","article-title":"Effects of abaloparatide-SC (BA058) on bone histology and histomorphometry: the ACTIVE phase 3 trial","volume":"97","author":"Moreira","year":"2017","journal-title":"Bone"},{"issue":"9041","key":"10.1002\/14651858.CD013424.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1007\/BF01623005","article-title":"Design of the Fracture Intervention Trial","volume":"3 Suppl 3","author":"Black","year":"1993","journal-title":"Osteoporosis International"},{"issue":"24","key":"10.1002\/14651858.CD013424.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"8","key":"10.1002\/14651858.CD013424.pub2-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1359\/JBMR.040326","article-title":"Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension","volume":"19","author":"Ensrud","year":"2004","journal-title":"Journal of Bone & Mineral Research"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1359\/jbmr.070112","article-title":"Alendronate treatment in women with normal to severely impaired renal function: an analysis of the fracture intervention trial","volume":"22","author":"Jamal","year":"2007","journal-title":"Journal of Bone & Mineral Research"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0012|cit12","first-page":"Suppl 10","article-title":"Safety and efficacy of denosumab among subjects with mild-to-moderate chronic kidney disease (CKD) in the fracture reduction evaluation of denosumab in osteoporosis every 6 months. Extension study [abstract no: 1889]","volume":"69","author":"Broadwell","year":"2017","journal-title":"Arthritis & Rheumatology"},{"issue":"8","key":"10.1002\/14651858.CD013424.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJMoa0809493","article-title":"Denosumab for prevention of fractures in postmenopausal women with osteoporosis [Erratum in: N Engl J Med. 2009 Nov 5;361(19):1914]","volume":"361","author":"Cummings","year":"2009","journal-title":"New England Journal of Medicine"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013424.pub2-BIB0014|cit14","first-page":"640A","article-title":"Treatment of osteoporosis by RANKL inhibition with denosumab in women at high cardiovascular risk and with renal impairment does not accelerate vascular calcification [abstract no: SA-PO2319]","volume":"21","author":"Egbuna","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013424.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"S207","DOI":"10.1016\/j.bone.2010.04.491","article-title":"The effects of denosumab on bone mineral density (BMD) and fracture by level of renal function [abstract no: PP355]","volume":"47","author":"Jamal","year":"2010","journal-title":"Bone"},{"issue":"8","key":"10.1002\/14651858.CD013424.pub2-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/jbmr.403","article-title":"Effects of denosumab on fracture and bone mineral density by level of kidney function","volume":"26","author":"Jamal","year":"2011","journal-title":"Journal of Bone & Mineral Research"},{"issue":"5","key":"10.1002\/14651858.CD013424.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1111\/j.1532-5415.2006.00695.x","article-title":"Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective","volume":"54","author":"Boonen","year":"2006","journal-title":"Journal of the American Geriatrics Society"},{"issue":"11","key":"10.1002\/14651858.CD013424.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1359\/jbmr.060802","article-title":"Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis","volume":"21","author":"Chen","year":"2006","journal-title":"Journal of Bone & Mineral Research"},{"issue":"12","key":"10.1002\/14651858.CD013424.pub2-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1002\/art.20671","article-title":"Association of severe vertebral fractures with reduced quality of life: reduction in the incidence of severe vertebral fractures by teriparatide","volume":"50","author":"Crans","year":"2004","journal-title":"Arthritis & Rheumatism"},{"issue":"12","key":"10.1002\/14651858.CD013424.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.1210\/jc.2007-0239","article-title":"Response to teriparatide in patients with baseline 25-hydroxyvitamin D insufficiency or sufficiency","volume":"92","author":"Dawson-Hughes","year":"2007","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.bone.2006.02.003","article-title":"Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover","volume":"39","author":"Delmas","year":"2006","journal-title":"Bone"},{"issue":"3","key":"10.1002\/14651858.CD013424.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1210\/jc.2004-0826","article-title":"Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures","volume":"90","author":"Gallagher","year":"2005","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"7","key":"10.1002\/14651858.CD013424.pub2-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1185\/030079905X49671","article-title":"The effects of teriparatide on the incidence of back pain in postmenopausal women with osteoporosis","volume":"21","author":"Genant","year":"2005","journal-title":"Current Medical Research & Opinion"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.bone.2005.04.023","article-title":"Reduction in vertebral fracture risk in teriparatide-treated postmenopausal women as assessed by spinal deformity index","volume":"37","author":"Genant","year":"2005","journal-title":"Bone"},{"issue":"11","key":"10.1002\/14651858.CD013424.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1359\/jbmr.2003.18.11.1932","article-title":"Recombinant human parathyroid hormone (1-34) [teriparatide] improves both cortical and cancellous bone structure","volume":"18","author":"Jiang","year":"2003","journal-title":"Journal of Bone & Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.bone.2011.10.018","article-title":"Teriparatide and the risk of nonvertebral fractures in women with postmenopausal osteoporosis","volume":"50","author":"Krege","year":"2012","journal-title":"Bone"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00198-006-0189-8","article-title":"Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment","volume":"18","author":"Miller","year":"2007","journal-title":"Osteoporosis International"},{"issue":"19","key":"10.1002\/14651858.CD013424.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"New England Journal Medicine"},{"issue":"8","key":"10.1002\/14651858.CD013424.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"4644","DOI":"10.1210\/jc.2004-2489","article-title":"Bone mineral and collagen quality in iliac crest biopsies of patients given teriparatide: new results from the Fracture Prevention Trial","volume":"90","author":"Paschalis","year":"2005","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s00223-010-9424-6","article-title":"Pharmacokinetics of teriparatide (rhPTH[1-34]) and calcium pharmacodynamics in postmenopausal women with osteoporosis","volume":"87","author":"Satterwhite","year":"2010","journal-title":"Calcified Tissue International"},{"issue":"12","key":"10.1002\/14651858.CD013424.pub2-BIB0031|cit31","first-page":"2405","article-title":"Relationship of health related quality of life to prevalent and new or worsening back pain in postmenopausal women with osteoporosis","volume":"32","author":"Silverman","year":"2005","journal-title":"Journal of Rheumatology"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/j.bone.2005.03.003","article-title":"Effects of teriparatide [rhPTH (1-34)] treatment on structural geometry of the proximal femur in elderly osteoporotic women","volume":"36","author":"Uusi-Rasi","year":"2005","journal-title":"Bone"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1359\/jbmr.081256","article-title":"Vertebral fracture risk is reduced in women who lose femoral neck BMD with teriparatide treatment","volume":"24","author":"Watts","year":"2009","journal-title":"Journal of Bone & Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0034|cit34","first-page":"461","article-title":"Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5 [Erratum in: Iran J Kidney Dis. 2015 Jan;9(1):76; PMID: 25599744]","volume":"8","author":"Haghverdi","year":"2014","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0035|cit35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1081\/JDI-48241","article-title":"Estrogen receptor (ER) gene polymorphism may predict the bone mineral density response to raloxifene in postmenopausal women on chronic hemodialysis","volume":"27","author":"Heilberg","year":"2005","journal-title":"Renal Failure"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1046\/j.1523-1755.2003.00005.x","article-title":"Effects of raloxifene on bone metabolism and serum lipids in postmenopausal women on chronic hemodialysis","volume":"63","author":"Hernandez","year":"2003","journal-title":"Kidney International"},{"issue":"Sept","key":"10.1002\/14651858.CD013424.pub2-BIB0037|cit37","first-page":"563","article-title":"The effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone resorption markers and serum lipids in postmenopausal women on chronic hemodialysis (HD) [abstract no: A2974]","volume":"11","author":"Hernandez","year":"2000","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD013424.pub2-BIB0038|cit38","first-page":"743A","article-title":"One year controlled study on the effect of raloxifene, a selective estrogen receptor modulator (SERM), on bone metabolism and serum lipids on postmenopausal women on chronic hemodialysis (HD) [abstract no: A3879]","volume":"12","author":"Hernandez","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"85","key":"10.1002\/14651858.CD013424.pub2-BIB0039|cit39","first-page":"S62","article-title":"Selective estrogen receptor modulators in chronic renal failure","volume":"63","author":"Heilberg","year":"2003","journal-title":"Kidney International - Supplement"},{"issue":"17","key":"10.1002\/14651858.CD013424.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.2165\/00019053-200422170-00005","article-title":"Cost effectiveness of raloxifene in the treatment of osteoporosis in Sweden: an economic evaluation based on the MORE study","volume":"22","author":"Borgstrom","year":"2004","journal-title":"Pharmacoeconomics"},{"issue":"7","key":"10.1002\/14651858.CD013424.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators [Erratum in: JAMA 1999 Dec 8;282(22):2124]","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"issue":"7","key":"10.1002\/14651858.CD013424.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1681\/ASN.2007050555","article-title":"The effect of raloxifene treatment in postmenopausal women with CKD","volume":"19","author":"Ishani","year":"2008","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD013424.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1359\/jbmr.040211","article-title":"Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study","volume":"19","author":"Johnell","year":"2004","journal-title":"Journal of Bone & Mineral Research"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s00198-004-1688-0","article-title":"Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporosis International"},{"issue":"Abstracts","key":"10.1002\/14651858.CD013424.pub2-BIB0045|cit45","first-page":"544A","article-title":"The protective effects on kidney function of 4 years of treatment with raloxifene, a selective estrogen receptor modulator: results from the MORE trial [abstract no: SA-PO915]","volume":"18","author":"Melamed","year":"2007","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0046|cit46","first-page":"140","article-title":"Prevalence of depressive symptoms in postmenopausal women with low bone mineral density and\/or prevalent vertebral fracture: results from the Multiple Outcomes of Raloxifene Evaluation (MORE) study","volume":"34","author":"Silverman","year":"2007","journal-title":"Journal of Rheumatology"},{"issue":"11","key":"10.1002\/14651858.CD013424.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1007\/s001980200125","article-title":"Effects of raloxifene on fracture severity in postmenopausal women with osteoporosis: results from the MORE study. Multiple Outcomes of Raloxifene Evaluation","volume":"13","author":"Siris","year":"2002","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s00198-005-0028-3","article-title":"Structural effects of raloxifene on the proximal femur: results from the Multiple Outcomes of Raloxifene Evaluation trial","volume":"17","author":"Uusi-Rasi","year":"2006","journal-title":"Osteoporosis International"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00044011-200626040-00006","article-title":"Effect of etidronic acid on arterial calcification in dialysis patients","volume":"26","author":"Ariyoshi","year":"2006","journal-title":"Clinical Drug Investigation"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013424.pub2-BIB0050|cit50","first-page":"S472","article-title":"Effects of intravenous ibandronate injection on renal function in postmenopausal women with osteoporosis at high risk for renal disease compared with ibandronate infusion or oral alendronate-the DIVINE study [abstract no: MO0382]","volume":"25","author":"Miller","year":"2010","journal-title":"Journal of Bone & Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.bone.2011.09.035","article-title":"Effects of intravenous ibandronate injection on renal function in women with postmenopausal osteoporosis at high risk for renal disease--the DIVINE study","volume":"49","author":"Miller","year":"2011","journal-title":"Bone"},{"issue":"12","key":"10.1002\/14651858.CD013424.pub2-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1007\/s001980200135","article-title":"A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial","volume":"13","author":"Fukunaga","year":"2002","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12882-017-0478-9","article-title":"Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials","volume":"18","author":"Shigematsu","year":"2017","journal-title":"BMC Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD013424.pub2-BIB0054|cit54","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/S0041-1345(98)00557-0","article-title":"Treatment of bone pain after kidney transplantation","volume":"30","author":"Grotz","year":"1998","journal-title":"Transplantation Proceedings"},{"issue":"8","key":"10.1002\/14651858.CD013424.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1097\/00007890-199810270-00007","article-title":"Treatment of osteopenia and osteoporosis after kidney transplantation","volume":"66","author":"Grotz","year":"1998","journal-title":"Transplantation"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.bone.2013.10.017","article-title":"Efficacy, tolerability and safety of once-monthly administration of 75mg risedronate in Japanese patients with involutional osteoporosis: a comparison with a 2.5mg once-daily dosage regimen","volume":"59","author":"Hagino","year":"2014","journal-title":"Bone"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1007\/s00774-018-0977-1","article-title":"Efficacy and safety of once-monthly risedronate in osteoporosis subjects with mild-to-moderate chronic kidney disease: a post hoc subgroup analysis of a phase III trial in Japan","volume":"37","author":"Sugimoto","year":"2019","journal-title":"Journal of Bone & Mineral Metabolism"},{"issue":"3","key":"10.1002\/14651858.CD013424.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1526-0968.2004.00136.x","article-title":"Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients","volume":"8","author":"Hashiba","year":"2004","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/j.1744-9987.2006.00345.x","article-title":"Inhibition of the progression of aortic calcification by etidronate treatment in hemodialysis patients: long-term effects","volume":"10","author":"Hashiba","year":"2006","journal-title":"Therapeutic Apheresis & Dialysis"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/jbmr.3676","article-title":"Effects of denosumab and alendronate on bone health and vascular function in hemodialysis patients: a randomized, controlled trial","volume":"34","author":"Iseri","year":"2019","journal-title":"Journal of Bone & Mineral Research"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0061|cit61","first-page":"83","article-title":"The effect of low dose hormone replacement therapy or SERM on bone metabolism in hemodialysis patients","volume":"14","author":"Hamano","year":"2000","journal-title":"Osteoporosis (Japan)"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0062|cit62","unstructured":"Ito T The effect of low dose hormone replacement therapy or raloxifene on bone and lipid metabolism in hemodialysis patients upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000000480"},{"issue":"5","key":"10.1002\/14651858.CD013424.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00774-006-0706-z","article-title":"Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen","volume":"24","author":"Kishimoto","year":"2006","journal-title":"Journal of Bone & Mineral Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12882-017-0478-9","article-title":"Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials","volume":"18","author":"Shigematsu","year":"2017","journal-title":"BMC Nephrology"},{"issue":"Program & Abstr","key":"10.1002\/14651858.CD013424.pub2-BIB0065|cit65","first-page":"358A","article-title":"Effects of short-term alendronate on bone mineral density in end stage renal disease [abstract no: A1842]","volume":"12","author":"Kleinstueck","year":"2001","journal-title":"Journal of the American Society of Nephrology"},{"issue":"5","key":"10.1002\/14651858.CD013424.pub2-BIB0066|cit66","first-page":"469","article-title":"A comparison of incidences of vertebral fracture in Japanese patients with involutional osteoporosis treated with risedronate and etidronate: a randomized, double-masked trial","volume":"22","author":"Kushida","year":"2006","journal-title":"Journal of Bone & Mineral Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0067|cit67","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s12882-017-0478-9","article-title":"Risedronate therapy in patients with mild-to-moderate chronic kidney disease with osteoporosis: post-hoc analysis of data from the risedronate phase III clinical trials","volume":"18","author":"Shigematsu","year":"2017","journal-title":"BMC Nephrology"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0068|cit68","unstructured":"Kao TW Can alendronate suppress calcification and improve bone density in chronic peritoneal dialysis patients? www.clinicaltrials.gov\/show\/NCT00261625"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0069|cit69","unstructured":"Lai CF Alendronate for vascular calcification in peritoneal dialysis patients? www.clinicaltrials.gov\/show\/NCT00299572"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0070|cit70","first-page":"420","article-title":"Comparison of alendronate and pamidronate on bone loss in kidney transplant patients for the first 6 months of transplantation [Erratum in: Iran J Kidney Dis. 2012 Jul;6(4):321]","volume":"5","author":"Omidvar","year":"2011","journal-title":"Iranian Journal of Kidney Diseases"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013424.pub2-BIB0071|cit71","first-page":"170","article-title":"Comparison the effect of alendronate and pamidronate on early BMD changes in kidney transplant patients in the first 6 months of transplantation [abstract no: 0740]","volume":"13","author":"Omidvar","year":"2010","journal-title":"International Journal of Rheumatic Diseases"},{"issue":"Suppl 3","key":"10.1002\/14651858.CD013424.pub2-BIB0072|cit72","doi-asserted-by":"crossref","first-page":"iii216","DOI":"10.1093\/ndt\/gfv177.34","article-title":"Effects on bone tissue of 12 months' combined treatment with alfacalcidol and strontium ranelate in patients with mild to moderate chronic renal failure [abstract no: FP435]","volume":"30","author":"Ruzhytska","year":"2015","journal-title":"Nephrology Dialysis Transplantation"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"464","DOI":"10.5812\/ijem.3794","article-title":"Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes","volume":"10","author":"Saito","year":"2012","journal-title":"International Journal of Endocrinology & Metabolism"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013424.pub2-BIB0074|cit74","first-page":"836A","article-title":"Is pamidronate more effective than alendronate in adult patients for the prevention of bone loss after kidney transplantation? [abstract no: PUB116]","volume":"21","author":"Sirsat","year":"2010","journal-title":"Journal of the American Society of Nephrology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD013424.pub2-BIB0075|cit75","first-page":"A2","article-title":"Randomised placebo-controlled trial of alendronate on vascular calcification in patients with chronic kidney disease [abstract no: 008]","volume":"14","author":"Toussaint","year":"2009","journal-title":"Nephrology"},{"issue":"Abstract Suppl","key":"10.1002\/14651858.CD013424.pub2-BIB0076|cit76","first-page":"81A","article-title":"Randomised placebo-controlled trial of alendronate on vascular calcification in patients with chronic kidney disease [abstract no: SA-FC345]","volume":"20","author":"Toussaint","year":"2009","journal-title":"Journal of the American Society of Nephrology"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1053\/j.ajkd.2009.12.039","article-title":"Effect of alendronate on vascular calcification in CKD stages 3 and 4: a pilot randomized controlled trial","volume":"56","author":"Toussaint","year":"2010","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0078|cit78","unstructured":"Mori K Impact of raloxifene, eldecalcitol and their combination therapy on bone indices in postmenopausal subjects with osteoporosis and chronic kidney disease stage 3: re Bone Study upload.umin.ac.jp\/cgi-open-bin\/ctr_e\/ctr_view.cgi?recptno=R000021054"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0079|cit79","first-page":"387","article-title":"Effects of salmon calcitonin in treatment of osteoporosis in patients undergoing dialysis","volume":"88","author":"Wang","year":"2008","journal-title":"Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal]"},{"issue":"14","key":"10.1002\/14651858.CD013424.pub2-BIB0080|cit80","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1097\/00029330-200807020-00007","article-title":"Salmon calcitonin in prevention of osteoporosis in maintenance dialysis patients","volume":"121","author":"Wang","year":"2008","journal-title":"Chinese Medical Journal"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0081|cit81","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1440-1797.2005.00436.x","article-title":"Effects of short-term alendronate on bone mineral density in haemodialysis patients","volume":"10","author":"Wetmore","year":"2005","journal-title":"Nephrology"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0082|cit82","unstructured":"Masmou B Effect of alendronate in patents with osteoporosis and chronic kidney disease en.irct.ir\/trial\/33312"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0083|cit83","unstructured":"Malluche H Renal osteodystrophy: an individual management approach www.clinicaltrials.gov\/show\/NCT02440581"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0084|cit84","unstructured":"Cristol JP Study evaluating denosumab on bone and vascular metabolism in osteoporotic chronic kidney disease (HDENO) www.clinicaltrials.gov\/show\/NCT02792413"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0085|cit85","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00198-013-2469-4","article-title":"Nationwide registry-based analysis of cardiovascular risk factors and adverse outcomes in patients treated with strontium ranelate","volume":"25","author":"Abrahamsen","year":"2014","journal-title":"Osteoporosis International"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0086|cit86","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1160\/TH07-07-0468","article-title":"Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis","volume":"99","author":"Adomaityte","year":"2008","journal-title":"Thrombosis & Haemostasis"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0087|cit87","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1046\/j.1523-1755.2000.00178.x","article-title":"Increased risk of hip fracture among patients with end-stage renal disease","volume":"58","author":"Alem","year":"2000","journal-title":"Kidney International"},{"issue":"10","key":"10.1002\/14651858.CD013424.pub2-BIB0088|cit88","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001347.pub2","article-title":"Bisphosphonates for steroid-induced osteoporosis","author":"Allen","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"3","key":"10.1002\/14651858.CD013424.pub2-BIB0089|cit89","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000276666","article-title":"Bisphosphonate use in chronic kidney disease: association with adynamic bone disease in a bone histology series","volume":"29","author":"Amerling","year":"2010","journal-title":"Blood Purification"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0090|cit90","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013424.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1002\/jbmr.1613","article-title":"A single-dose study of denosumab in patients with various degrees of renal impairment","volume":"27","author":"Block","year":"2012","journal-title":"Journal of Bone & Mineral Research"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0092|cit92","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1210\/jc.2007-2814","article-title":"Effects of denosumab on bone mineral density and bone turnover in postmenopausal women","volume":"93","author":"Bone","year":"2008","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"14","key":"10.1002\/14651858.CD013424.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1001\/archinte.1996.00440130053006","article-title":"Mortality following fractures in older women: the study of osteoporotic fractures","volume":"156","author":"Browner","year":"1996","journal-title":"Archives of Internal Medicine"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"51-62","DOI":"10.3111\/200104051062","article-title":"The cost of osteoporotic fractures in the UK: Projections for 2000-2020","volume":"4","author":"Burge","year":"2001","journal-title":"Journal of Medical Economics"},{"issue":"3","key":"10.1002\/14651858.CD013424.pub2-BIB0095|cit95","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1359\/jbmr.061113","article-title":"Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025","volume":"22","author":"Burge","year":"2007","journal-title":"Journal of Bone & Mineral Research"},{"issue":"16","key":"10.1002\/14651858.CD013424.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","article-title":"Romosozumab treatment in postmenopausal women with osteoporosis","volume":"375","author":"Cosman","year":"2016","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013424.pub2-BIB0097|cit97","doi-asserted-by":"crossref","first-page":"711","DOI":"10.7326\/M14-0317","article-title":"Comparative effectiveness of pharmacologic treatments to prevent fractures: an updated systematic review","volume":"161","author":"Crandall","year":"2014","journal-title":"Annals of Internal Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013424.pub2-BIB0098|cit98","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1053\/j.ajkd.2003.12.004","article-title":"Osteoporosis in chronic kidney disease","volume":"43","author":"Cunningham","year":"2004","journal-title":"American Journal of Kidney Diseases"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0099|cit99","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1159\/000380960","article-title":"Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5","volume":"41","author":"Dave","year":"2015","journal-title":"American Journal of Nephrology"},{"issue":"14","key":"10.1002\/14651858.CD013424.pub2-BIB0100|cit100","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"De Groen","year":"1996","journal-title":"New England Journal of Medicine"},{"issue":"3","key":"10.1002\/14651858.CD013424.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1097\/SPC.0b013e3283552d7d","article-title":"Atypical femoral fractures: epidemiology, etiology, and patient management","volume":"6","author":"Donnelly","year":"2012","journal-title":"Current Opinion in Supportive & Palliative Care"},{"issue":"5","key":"10.1002\/14651858.CD013424.pub2-BIB0102|cit102","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1210\/jc.2019-00221","article-title":"Pharmacological management of osteoporosis in postmenopausal women: an Endocrine Society* clinical practice guideline","volume":"104","author":"Eastell","year":"2019","journal-title":"Journal of Clinical Endocrinology & Metabolism"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0103|cit103","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD: summary of recommendation statements","volume":"3","author":"Eknoyan","year":"2013","journal-title":"Kidney International Supplements"},{"issue":"11","key":"10.1002\/14651858.CD013424.pub2-BIB0104|cit104","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1002\/jcph.738","article-title":"Compliance, persistence, and preferences regarding osteoporosis treatment during active therapy or drug holiday","volume":"56","author":"Eliasaf","year":"2016","journal-title":"Journal of Clinical Pharmacology"},{"issue":"10053","key":"10.1002\/14651858.CD013424.pub2-BIB0105|cit105","first-page":"1459","article-title":"Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015 [Erratum in: Lancet. 2017 Jan 7;389(10064):e1; PMID: 28091379]","volume":"388","author":"GBD 2015 Mortality and Causes of Death Collaborators","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"10.1002\/14651858.CD013424.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/ki.2012.65","article-title":"The implications of anatomical and functional changes of the aging kidney: with an emphasis on the glomeruli","volume":"82","author":"Glassock","year":"2012","journal-title":"Kidney International"},{"issue":"7650","key":"10.1002\/14651858.CD013424.pub2-BIB0107|cit107","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"Journal of Clinical Epidemiology"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0109|cit109","unstructured":"He W Goodkind D Kowal P An Aging World: 2015 www.census.gov\/content\/dam\/Census\/library\/publications\/2016\/demo\/p95-16-1.pdf"},{"issue":"7414","key":"10.1002\/14651858.CD013424.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0111|cit111","unstructured":"Higgins JP Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0112|cit112","unstructured":"International Society for Clinical Densitometry (ISCD) Skeletal health assessment In children from infancy to adolescence https:\/\/iscd.org\/learn\/official-positions\/pediatric-positions"},{"issue":"12","key":"10.1002\/14651858.CD013424.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporosis International"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00198-004-1780-5","article-title":"Assessment of fracture risk","volume":"16","author":"Kanis","year":"2005","journal-title":"Osteoporosis International"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0115|cit115","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00198-018-4704-5","article-title":"European guidance for the diagnosis and management of osteoporosis in postmenopausal women [Erratum in: Osteoporos Int. 2020 Jan;31(1):209; PMID: 31673731] [Erratum in: Osteoporos Int. 2020 Apr;31(4):801; PMID: 32072205]","volume":"30","author":"Kanis","year":"2019","journal-title":"Osteoporosis International"},{"issue":"113","key":"10.1002\/14651858.CD013424.pub2-BIB0116|cit116","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)","volume":"Aug","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group","year":"2009","journal-title":"Kidney International - Supplement"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0117|cit117","first-page":"1","article-title":"KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) [Erratum in: Kidney Int Suppl (2011). 2017 Dec;7(3):e1; PMID: 30681074]","volume":"7","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group","year":"2017","journal-title":"Kidney International Supplements"},{"issue":"6914","key":"10.1002\/14651858.CD013424.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1136\/bmj.307.6914.1248","article-title":"Mortality and morbidity after hip fractures","volume":"307","author":"Keene","year":"1993","journal-title":"BMJ"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1007\/s11914-018-0491-3","article-title":"Updates in CKD-associated osteoporosis","volume":"16","author":"Khairallah","year":"2018","journal-title":"Current Osteoporosis Reports"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0120|cit120","doi-asserted-by":"crossref","first-page":"962","DOI":"10.2215\/CJN.11031017","article-title":"Management of osteoporosis in CKD","volume":"13","author":"Khairallah","year":"2018","journal-title":"Clinical Journal of The American Society of Nephrology: CJASN"},{"issue":"10","key":"10.1002\/14651858.CD013424.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1002\/jbmr.2862","article-title":"Hip fracture in patients with non-dialysis-requiring chronic kidney disease","volume":"31","author":"Kim","year":"2016","journal-title":"Journal of Bone & Mineral Research"},{"issue":"7","key":"10.1002\/14651858.CD013424.pub2-BIB0122|cit122","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s00198-003-1435-y","article-title":"Relationship between age, renal function and bone mineral density in the US population","volume":"14","author":"Klawansky","year":"2003","journal-title":"Osteoporosis International"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","article-title":"National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification [Erratum in: Ann Intern Med. 2003 Oct 7;139(7):605]","volume":"139","author":"Levey","year":"2003","journal-title":"Annals of Internal Medicine"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/sj.ki.5002009","article-title":"Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease [Erratum in: Kidney Int. 2009 Jun 1;75(11):1237; PMID: 30036915]","volume":"71","author":"Levin","year":"2007","journal-title":"Kidney International"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0125|cit125","volume-title":"Brenner and Rector's The Kidney","volume":"2","author":"Llach","year":"2000"},{"issue":"5","key":"10.1002\/14651858.CD013424.pub2-BIB0126|cit126","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"New England Journal of Medicine"},{"issue":"2","key":"10.1002\/14651858.CD013424.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.bone.2008.04.007","article-title":"Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial","volume":"43","author":"Miller","year":"2008","journal-title":"Bone"},{"issue":"7","key":"10.1002\/14651858.CD013424.pub2-BIB0128|cit128","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jama.2016.11136","article-title":"Effect of Abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial [Erratum in: JAMA. 2017 Jan 24;317(4):442; PMID: 28118431]","volume":"316","author":"Miller","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0129|cit129","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Annals of Internal Medicine"},{"issue":"10","key":"10.1002\/14651858.CD013424.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/1060028018768808","article-title":"Denosumab: a unique perspective on adherence and cost-effectiveness compared with oral bisphosphonates in osteoporosis patients","volume":"52","author":"Morizio","year":"2018","journal-title":"Annals of Pharmacotherapy"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.reuma.2018.09.004","article-title":"Recommendations by the Spanish Society of Rheumatology on Osteoporosis","volume":"15","author":"Naranjo Hern\u00e1ndez","year":"2019","journal-title":"Reumatolog\u00eda Cl\u00ednica"},{"issue":"9","key":"10.1002\/14651858.CD013424.pub2-BIB0132|cit132","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"10.1002\/14651858.CD013424.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1681\/ASN.2005111194","article-title":"Relationship between moderate to severe kidney disease and hip fracture in the United States","volume":"17","author":"Nickolas","year":"2006","journal-title":"Journal of the American Society of Nephrology"},{"issue":"6","key":"10.1002\/14651858.CD013424.pub2-BIB0134|cit134","first-page":"569-73","article-title":"NIH Consensus Development Panel on Osteoporosis Prevention. Diagnosis, and Therapy, March 7-29, 2000: highlights of the conference","volume":"94","author":"NIH Consensus Development Panel","year":"2001","journal-title":"Southern Medical Journal"},{"issue":"24","key":"10.1002\/14651858.CD013424.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.2169\/internalmedicine.8618-16","article-title":"Management of osteoporosis in chronic kidney disease","volume":"56","author":"Nitta","year":"2017","journal-title":"Internal Medicine"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0136|cit136","unstructured":"National Osteoporosis Guideline Group NOGG 2017: Clinical guideline for the prevention and treatment of osteoporosis www.sheffield.ac.uk\/NOGG\/NOGG%20Guideline%202017.pdf"},{"issue":"7","key":"10.1002\/14651858.CD013424.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2165\/11533770-000000000-00000","article-title":"Incidence of venous thromboembolism in users of strontium ranelate: an analysis of data from a prescription-event monitoring study in England","volume":"33","author":"Osborne","year":"2010","journal-title":"Drug Safety"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0138|cit138","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD008175","article-title":"Vitamin D compounds for people with chronic kidney disease not requiring dialysis","author":"Palmer","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0139|cit139","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005633.pub2","article-title":"Vitamin D compounds for people with chronic kidney disease requiring dialysis","author":"Palmer","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"10","key":"10.1002\/14651858.CD013424.pub2-BIB0140|cit140","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005015.pub4","article-title":"Interventions for preventing bone disease in kidney transplant recipients","author":"Palmer","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"11","key":"10.1002\/14651858.CD013424.pub2-BIB0141|cit141","doi-asserted-by":"crossref","first-page":"818","DOI":"10.7326\/M15-1361","article-title":"Treatment of low bone density or osteoporosis to prevent fractures in men and women: a clinical practice guideline update from the American College of Physicians [Erratum in: Ann Intern Med. 2017 Sep 19;167(6):448; PMID: 28975328]","volume":"166","author":"Qaseem","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"7","key":"10.1002\/14651858.CD013424.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","article-title":"Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis","volume":"30","author":"Reginster","year":"2019","journal-title":"Osteoporosis International"},{"issue":"5","key":"10.1002\/14651858.CD013424.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","article-title":"Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases","volume":"62","author":"Ruggiero","year":"2004","journal-title":"Journal of Oral & Maxillofacial Surgery"},{"issue":"8","key":"10.1002\/14651858.CD013424.pub2-BIB0144|cit144","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006023.pub3","article-title":"Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD)","author":"Ruospo","year":"2018","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"15","key":"10.1002\/14651858.CD013424.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","article-title":"Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis","volume":"377","author":"Saag","year":"2017","journal-title":"New England Journal of Medicine"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0146|cit146","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Vist GE Glasziou P Guyatt GH Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0147|cit147","unstructured":"Sch\u00fcnemann HJ Oxman AD Higgins JP Deeks JJ Glasziou P Guyatt GH Chapter 12: Interpreting results and drawing conclusions. In: Higgins JP, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0148|cit148","unstructured":"The SONG Handbook Version 1.0 www.songinitiative.org\/reports-and-publications\/ 2017"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1053\/j.ajkd.2015.06.023","article-title":"Diagnostic accuracy of bone turnover markers and bone histology in patients with CKD treated by dialysis","volume":"67","author":"Sprague","year":"2016","journal-title":"American Journal of Kidney Diseases"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S0272-6386(96)90461-8","article-title":"Prevalence and risk factors for osteopenia in dialysis patients","volume":"28","author":"Stein","year":"1996","journal-title":"American Journal of Kidney Diseases"},{"issue":"1","key":"10.1002\/14651858.CD013424.pub2-BIB0151|cit151","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/ki.2013.279","article-title":"High rates of death and hospitalization follow bone fracture among hemodialysis patients","volume":"85","author":"Tentori","year":"2013","journal-title":"Kidney International"},{"issue":"4","key":"10.1002\/14651858.CD013424.pub2-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD005324.pub2","article-title":"Bisphosphonate therapy for children and adolescents with secondary osteoporosis","author":"Ward","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD013424.pub2-BIB0153|cit153","unstructured":"World Health Organization Assessment of fracture risk and its implication to screening for postmenopausal osteoporosis: Technical report series 843 apps.who.int\/iris\/handle\/10665\/39142"},{"issue":"9","key":"10.1002\/14651858.CD013424.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"649","DOI":"10.7326\/M16-2752","article-title":"Benefits and harms of osteoporosis medications in patients with chronic kidney disease","volume":"166","author":"Wilson","year":"2017","journal-title":"Annals of Internal Medicine"},{"issue":"9","key":"10.1002\/14651858.CD013424.pub2-BIB0155|cit155","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD013424","article-title":"Pharmacological interventions for osteoporosis in people with chronic kidney disease stages 3-5D","author":"Hara","year":"2019","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T16:43:48Z","timestamp":1673369028000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD013424.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Kidney and Transplant Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,7]]},"references-count":155,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd013424.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,7]]}}}